Low Anterior Resection Syndrome
Conditions
Brief summary
The primary endpoint will be change of the main symptom score assessed by the Measure Yourself Medical Outcome Profile (MYMOP) score comparing the TAI group to the glycerol suppository group.
Detailed description
1. Assessment of bowel function with the LARS Score (27) and the Memorial Sloan-Kettering Cancer Centre (MSKCC) Bowel Function Instrument (BFI) (28)). 2. Assessment of the faecal incontinence status with The St. Mark’s Incontinence Score (29). 3. Assessment of QOL and bowel function-related QOL with the EORTC QLQ-C30 and EORTC QLQ-CR29 (30,31). 4. Assessment of urinary function with The International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms (ICIQ-M/F-L
Interventions
DRUGGlycerol "OBA"
DRUGsuppositorier
Sponsors
Region Midtjylland
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint will be change of the main symptom score assessed by the Measure Yourself Medical Outcome Profile (MYMOP) score comparing the TAI group to the glycerol suppository group. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Assessment of bowel function with the LARS Score (27) and the Memorial Sloan-Kettering Cancer Centre (MSKCC) Bowel Function Instrument (BFI) (28)). 2. Assessment of the faecal incontinence status with The St. Mark’s Incontinence Score (29). 3. Assessment of QOL and bowel function-related QOL with the EORTC QLQ-C30 and EORTC QLQ-CR29 (30,31). 4. Assessment of urinary function with The International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms (ICIQ-M/F-L | — |
Countries
Denmark
Outcome results
None listed